Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided response claims the topic-specific safety content (opioid co-use risks, abuse/misuse/addiction, and dependence/withdrawal) is supported by the FDA label excerpts, and it does not assert any label-inconsistent statements for these topics.
Category Scores
Accurate Statements
The claim topics (opioid co-use risks; abuse/misuse/addiction; dependence and withdrawal) align with FDA-approved boxed warning content and related labeled warnings.
Supported by the provided label excerpts in WARNING 1 and related sections (5.1, 5.2, 5.3, and 7.3) for the specified topics.
No dangerous omission is apparent for these specific topics.
The provided label excerpts explicitly cover concomitant opioid risks, abuse/misuse/addiction, and dependence/withdrawal, as reflected in the cited sections (1, 5.1-5.3, 7.3).
Unsupported Statements
adheres_to_label
This is a conclusion about overall adherence; it is not a specific label-supported factual claim, though it is consistent with the cited topic coverage.
Contradictions
Important Omissions
No explicit, quoted description of the specific dose/duration/monitoring instructions for opioid co-use (e.g., 'lowest effective dosages and minimum durations' and 'follow patients closely') is included in the response itself; the response only describes that such guidance exists in the label.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response does not introduce incorrect or unsafe medical instructions; it only asserts that the label warnings for the specified topics are covered and that no dangerous omission is detected for those topics.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response provides mostly high-level conclusions rather than directly reproducing the exact label wording/instructions.
Suggested Improvement
For greater label fidelity, include the specific operational label directives for opioid co-use (e.g., reserve concomitant prescribing, lowest effective dose, minimum duration, and close patient follow-up) and for dependence/withdrawal (gradual taper vs abrupt discontinuation) as direct quotes or near-quotes.